Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)

The aim of the study was to investigate the efficacy of the antibiotic minocycline as a drug treatment in patients with Multiple‐System‐Atrophy Parkinson‐type (MSA‐P). Sixty‐three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple‐System‐Atrophy Rating‐Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified‐Parkinson's‐Disease Rating‐Scale (UPDRS). Health‐related quality of life (HrQoL) was assessed using the EQ‐5D and SF‐12. “Progression rate” was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow‐up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. “progression rate” was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5)[11C](R)‐PK11195‐PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)‐PK11195 binding actually decreased. These preliminary PET‐data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double‐blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function. © 2009 Movement Disorder Society

[1]  Ninds Net-Pd Investigators.  A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results , 2008, Clinical neuropharmacology.

[2]  R A Robb,et al.  A software system for interactive and quantitative visualization of multidimensional biomedical images. , 1991, Australasian physical & engineering sciences in medicine.

[3]  R. Ferrante,et al.  Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Schwarz,et al.  Microglial activation in multiple system atrophy: a potential role for NF‐κB/rel proteins , 1998, Neuroreport.

[5]  T. Mizutani,et al.  Microglial Activation Parallels System Degeneration in Multiple System Atrophy , 2004, Journal of neuropathology and experimental neurology.

[6]  J. O'dell,et al.  Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. , 2001, Arthritis and rheumatism.

[7]  J. R. Mitchell,et al.  The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study , 2007, Multiple sclerosis.

[8]  R. Davis,et al.  Textbook of Neuropathology , 1996 .

[9]  R. Ashley,et al.  How do Tetracyclines Work? , 1998, Advances in dental research.

[10]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[11]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[12]  D J Brooks,et al.  Microglial activation correlates with severity in Huntington disease , 2006, Neurology.

[13]  T. Hökfelt,et al.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Lemere,et al.  Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice , 2006, Glia.

[15]  F. Vilhardt.  Microglia: phagocyte and glia cell. , 2005, The international journal of biochemistry & cell biology.

[16]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[17]  E. Bézard,et al.  Rise and fall of minocycline in neuroprotection: need to promote publication of negative results , 2004, Experimental Neurology.

[18]  K. Santacruz,et al.  Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury , 2006, Journal of neurochemistry.

[19]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[20]  H. Robertson,et al.  Maintained improvement with minocycline of a patient with advanced Huntington's disease , 2002, Journal of psychopharmacology.

[21]  R B Banati,et al.  [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy , 2003, Neurology.

[22]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[23]  Ninds Net-Pd Investigators.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .

[24]  W. Hader,et al.  Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell‐microglia interaction , 2005, Journal of leukocyte biology.

[25]  R. Bonelli,et al.  Neuroprotection in Huntington's disease: a 2-year study on minocycline , 2004, International clinical psychopharmacology.

[26]  R. Elble,et al.  A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease , 2006, Neurology.

[27]  J. Koistinaho,et al.  Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia1 , 2001, The Journal of Immunology.

[28]  E. Tolosa,et al.  Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[29]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy , 2006, Movement disorders : official journal of the Movement Disorder Society.

[30]  A. Lawrence,et al.  Minocycline treatment attenuates microglia activation and non-angiotensin II [125I] CGP42112 binding in brainstem following nodose ganglionectomy , 2005, Neuroscience.

[31]  P. Riederer,et al.  Degeneration of neuronal cells due to oxidative stress--microglial contribution. , 2002, Parkinsonism & related disorders.

[32]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[33]  W. Schäbitz,et al.  MINOCYCLINE TREATMENT IN ACUTE STROKE: AN OPEN-LABEL, EVALUATOR-BLINDED STUDY , 2007, Neurology.

[34]  K. Schmid,et al.  Cell Death Mechanisms in Multiple System Atrophy , 1998, Journal of neuropathology and experimental neurology.

[35]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[36]  F. Pontieri,et al.  Minocycline in amyotrophic lateral sclerosis: a pilot study , 2005, Neurological Sciences.

[37]  Sid Gilman,et al.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) , 2004, Movement disorders : official journal of the Movement Disorder Society.

[38]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[39]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Rabin,et al.  EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.

[41]  Prasongchai Sattayaprasert,et al.  Minocycline inhibits neuronal death and glial activation induced by β‐amyloid peptide in rat hippocampus , 2004, Glia.

[42]  H U Rehman,et al.  Multiple system atrophy , 2001, Postgraduate medical journal.

[43]  E. Bézard,et al.  Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease , 2004, The European journal of neuroscience.

[44]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.